文献速递妇科

雌激素受体α免疫反应性预测深部子宫内膜异位症症状严重程度与疼痛复发

Estrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis.
PubMed 文献 · Fertil Steril · 2020-05-13

横断面研究纳入92例子宫内膜异位症患者,用组织微阵列和免疫组化IRS评分检测ER-α、PR、AR和芳香化酶表达,并与疼痛NRS评分行多因素logistic回归。ER-α表达与未激素治疗者的中重度痛经和深部性交痛相关,孕激素治疗者ER-α持续高表达与深部性交痛、严重排便痛及1年疼痛持续相关。

要点

  • ER-α表达与深部子宫内膜异位症疼痛严重程度最相关
  • 孕激素治疗可降低ER-α表达,但PR、AR和芳香化酶不变
  • 孕激素未能抑制ER-α者1年疼痛持续风险更高

核心结论

  • ER-α、PR、AR和芳香化酶均在深部子宫内膜异位症中表达,ER-α水平与症状严重程度最相关,提示ER是深部子宫内膜异位症的关键驱动因素。
  • 孕激素治疗与ER-α表达降低相关,但孕激素未能抑制ER-α也是1年疼痛严重程度和复发的预测因素。

研究设计与样本

  • 横断面研究,在大学医院纳入92例子宫内膜异位症女性,组织样本来自手术确诊患者。
  • 构建组织微阵列,用免疫组化IRS评分评估受体表达强度,临床变量与IRS行多因素logistic回归分析。
  • 结局指标为手术时及1年后痛经、深部性交痛、排便痛和非经期疼痛的存在与严重程度,采用数字评定量表NRS评估。

主要发现

  • ER-α、PR、AR和芳香化酶表达在研究参与者之间存在差异。
  • 孕激素治疗使ER-α表达降低,而PR、AR和芳香化酶表达未改变。
  • 未接受激素治疗的女性中,ER-α表达较高增加中重度痛经和深部性交痛的可能性。
  • 接受孕激素治疗的女性中,ER-α持续较高表达与深部性交痛、严重排便痛及1年时子宫内膜异位症相关疼痛持续更大的可能性相关。

临床怎么用

  • 对深部子宫内膜异位症患者可检测ER-α表达,辅助评估疼痛严重程度和复发风险。
  • 孕激素治疗中若ER-α未被抑制,提示1年疼痛持续风险较高,需加强随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the relationship between steroid receptor expression and pain symptoms in endometriosis. DESIGN: Cross-sectional SETTING: University Hospital PATIENT(S): Women with endometriosis (N = 92). INTERVENTION(S): Tissue samples were obtained from patients with surgically diagnosed endometriosis. MAIN OUTCOME MEASURE(S): A tissue microarray (TMA) was generated from patients with endometriosis. Data were collected on the presence and severity of dysmenorrhea, deep dyspareunia, dyschezia, and nonmenstrual pain by use of a numerical rating scale (NRS) at the time of surgery and after 1 year. The intensity of receptor expression was evaluated through immunohistochemistry and measured according to an immunoreactive score (IRS). Clinical variables were correlated to IRS by multivariate logistic regression analysis. RESULTS: Estrogen receptor-α (ER-α), progesterone receptor (PR), androgen receptor (AR), and aromatase expression differed among study participants. ER-α expression was reduced by progestin therapy, whereas of expressions of PR, AR, and aromatase were unchanged. Higher ER-α expression increased the likelihood of moderate to severe dysmenorrhea and deep dyspareunia in women not receiving hormonal treatment. In women receiving progestin therapy, persistently higher ER-α expression was correlated with greater likelihood of deep dyspareunia, severe dyschezia, and endometriosis-associated pain persistence at 1 year. CONCLUSION(S): ER-α, PR, AR, and aromatase were all expressed in deep endometriosis. ER-α levels best correlated with severity of symptoms, which suggests that ER is a key driver of deep endometriosis. Progestin treatment was associated with a reduction of ER-α expression; however, failure of ER suppression by progestins was also a predictor of pain severity and recurrence at 1 year.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Pluchino N, Mamillapalli R, Wenger JM, et al. Estrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis. Fertil Steril. 2020. PMID: 32416979. doi:10.1016/j.fertnstert.2020.01.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。